Johns Hopkins Bloomberg School of Public Health

jhsph.edu

Total trials

363

Active

53

Phase 3

39

Total enrollment

1,660,258

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 5 of 5 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
A package of oral health interventions, including a daily antiseptic oral rinse1
Nitazoxanide1
Artemether-lumefantrine1
Dihydroartemisinin-piperaquine1
Azithromycin1

Next readouts

  • 2020-08-24
  • 2028-12
  • 2028-12-31
  • 2029-08

Top conditions

  • HIV Infections20
  • Obesity20
  • HIV18
  • Surveys and Questionnaires11
  • Anxiety10
  • Noncommunicable Diseases10
  • Depression10
  • Substance Use9

Frequently asked questions about Johns Hopkins Bloomberg School of Public Health

How many clinical trials does Johns Hopkins Bloomberg School of Public Health have on ClinicalTrials.gov?
Johns Hopkins Bloomberg School of Public Health is listed as the lead sponsor on 363 clinical trials in ClinicalTrials.gov, 53 of which are currently active (recruiting, enrolling, or ongoing).
How many of Johns Hopkins Bloomberg School of Public Health's trials are in Phase 3?
39 of Johns Hopkins Bloomberg School of Public Health's trials are in Phase 3, spread across 5 active drug programs.
What therapeutic areas does Johns Hopkins Bloomberg School of Public Health focus on?
Johns Hopkins Bloomberg School of Public Health's most-studied conditions on ClinicalTrials.gov are HIV Infections, Obesity, HIV, Surveys and Questionnaires, Anxiety.
When are Johns Hopkins Bloomberg School of Public Health's next clinical trial readouts?
Johns Hopkins Bloomberg School of Public Health has 4 upcoming primary-completion readouts tracked here; the soonest is “Pharmacokinetics and Pharmacodynamics of the Gametocytocidal and Post-treatment Chemoprotective Effects of Antimalarials”, expected around 2020-08-24.